Invetech Wins 2025 Australian Good Design Award Gold for Excellence in Design and Innovation
SAN DIEGO, Oct. 17, 2025 /PRNewswire/ -- Invetech, a global leader in experience design-led instrument development, is proud to announce its work has been recognized with a prestigious 2025 Australian Good Design Award Gold for Digital Design Apps & Software. The award celebrates Invetech's commitment to human-centered design and its ability to...
Clarity signs copper-67 Supply Agreement with Nusano
SYDNEY, Oct. 16, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Supply Agreement for copper-67 with Nusano, Inc. ("Nusano"). Nusano's 190,000 square foot...
Volpara Earns ACR® Learning Network Vendor Partner Designation
LYNNWOOD, Wash., Oct. 16, 2025 /PRNewswire/ -- Volpara Health has qualified for the American College of Radiology® (ACR®) Learning Network Vendor Partner designation. Volpara Health partnered with one of the latest graduates of the ACR ImPower Program Mammography Positioning Improvement Collaborative to identify opportunities to improve breast cancer detection through optimized mammography positioning. ...
NYSE Content Advisory: Pre-Market Update + HPE Unveils Strategic Business Priorities
NEW YORK, Oct. 16, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + HPE Unveils Strategic Business Priorities ...
Unixell Biotech reported a case study of UX-DA001, an iPSC-derived autologous cell therapy for Parkinson Diseases at MDS Congress 2025
SHANGHAI, Oct. 16, 2025 /PRNewswire/ -- Unixell Biotech, a clinical-stage bitotech company focused on developing innovative cell therapies for Parkinson's disease (PD) and other neurological disorders, announced positive 6-month follow-up data from the first patient in its phase 1 clinical trial for UX-DA001, an iPSC-derived autologous cell therapy for PD. These data were presented on October 8th at the International Congress of Parkinson's Disease...
Microban International Appoints Shermon McMillan as New President
HUNTERSVILLE, N.C., Oct. 16, 2025 /PRNewswire/ -- Microban International, the global leader in antimicrobial and odor control solutions, today announced the appointment of Shermon McMillan as its new president. A seasoned global executive with a proven record of driving growth at Fortune 500 companies, McMillan will guide Microban strategy, operations and innovation...
NUH And NUS Launch New Molecular Imaging And Theranostic Centre To Strengthen Patient Care And Research
Powered by Singapore's first next-generation total-body PET/CT system, the new facility aims to transform diagnostics, treatment and research in cancer and beyond SINGAPORE, Oct. 16, 2025 /PRNewswire/ -- The National University Hospital (NUH) and the National University of Singapore (NUS) Clinical Imaging Research Centre (CIRC) have jointly launched the Molecular Imaging and Theranostic Centre, a novel integrated...
SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology
BOSTON and ROLLE, Switzerland, Oct. 16, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in AI-driven precision medicine, today announced the launch of SOPHiA DDM™ Digital Twins, a breakthrough research technology that creates dynamic, virtual representations of individual patients to simulate potential outcomes and help oncologists make better treatment decisions. SOPHiA...
HARMONi-6 Phase III Study of Ivonescimab Accepted by The Lancet and Selected for ESMO 2025 LBA Presentation
HONG KONG, Oct. 16, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) today announced that the groundbreaking results from the registrational Phase III AK112-306/HARMONi-6 study of ivonescimab have been accepted for publication in The Lancet. The study evaluated ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, combined with chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung...
Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights
At ASHG, an early access customer from the London Health Sciences Center Research Institute demonstrated the power of the 5-base genome for accelerating resolution of rare disease cases Proprietary 5-base chemistry and novel DRAGEN algorithms enable dual-omic inquiry, providing researchers with new tool for precision medicine breakthroughs SAN DIEGO, Oct. 16, 2025...
